. 2017 Oct 31;8(63):107022–107032. doi: 10.18632/oncotarget.22206

Table 3. The adverse factors for early treatment response.

	1^st cycle-MMR			2^nd cycle cumulate-MMR			MRD-negative
	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Univariate factors ^a
Gender (male vs. female)	1.69	0.60-4.73	0..319	1.20	0.45-3.23	0.712	0.96	0.37-2.49	0.924
Age (≥35y vs. <35y)	2.10	0.67-6.54	0.200	1.24	0.47-3.24	0.667	1.16	0.44-3.04	0.763
WBC (≥1000×10⁹/l vs.<100×10⁹/l)	1.66	0.58-4.71	0.342	2.44	0.95-6.27	0.064	1.22	0.48-3.08	0.677
EGIL classification (BAL vs. ALL)	4.11	0.49-34.56	0.193	1.68	0.44-6.38	0.446	0.68	0.18-2.56	0.563
ACA (with vs. without)	1.12	0.41-3.08	0.825	0.74	0.29-1.89	0.530	1.41	0.56-3.56	0.468
BCR/ABL1 (P210 vs. P190)	7.74	1.65-36.41	0.010	2.55	0.97-6.74	0.059	3.47	1.20-10.05	0.022
ABL1 gene mutations (yes vs. no)	2.75E8	2.75E8	<0.001	1.13E8	1.13E8	<0.001	4.73E7	4.73E7	<0.001
The generation of TKI (2^nd vs. 1^st)	1.79	0.63-5.06	0.276	1.41	0.56-3.56	0.468	1.33	0.53-3.37	0.543
Multivariate factors^b
BCR/ABL1 (P210 vs. P190)	7.99	1.53-41.86	0.014				4.80	1.38-16.77	0.014
ABL1 gene mutations (yes vs. no)	4.86E7	4.86E7	<0.001	2.31E8	2.31E8	<0.001	6.92E7	6.92E7	<0.001

Abbreviations: HR, hazard ratio; 95%CI, 95% confidence interval

^a Factors with P<0.10 in the univariate analyses were subjected to multivariate analysis afterwards.

^b Backward stepwise Cox proportional-hazard modeling was used in multivariate analysis of risk factors.